Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists

Hosp Pediatr. 2024 Mar 1;14(3):e170-e172. doi: 10.1542/hpeds.2023-007639.

Authors

Elena Aragona¹, Neha S Joshi², Krista L Birnie³, Poj Lysouvakon⁴, Rakhi Gupta Basuray⁵

Affiliations

¹ Yale School of Medicine, New Haven, Connecticut.
² Stanford University School of Medicine, Stanford, California.
³ Seattle Children's Hospital, Seattle, Washington.
⁴ University of Chicago Medicine, Chicago, Illinois.
⁵ Nationwide Children's Hospital, Columbus, Ohio.

PMID: 38115681
DOI: 10.1542/hpeds.2023-007639

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Hospitalists*
Humans
Infant, Newborn

Substances

nirsevimab
Antibodies, Monoclonal, Humanized